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Abstract
Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with unknown
etiology. Interferon-b (IFN-b), a member of the type I IFN family, is used as a therapeutic for MS and the IFN
signaling pathway is implicated in MS susceptibility. Interferon regulatory factor 7 (IRF7) is critical for the induction
and positive feedback regulation of type I IFN. To establish whether and how endogenous type I IFN signaling
contributes to disease modulation and to better understand the underlying mechanism, we examined the role of
IRF7 in the development of MS-like disease in mice.
Methods: The role of IRF7 in development of EAE was studied by immunizing IRF7-KO and C57BL/6 (WT) mice
with myelin oligodendrocyte glycoprotein using a standard protocol for the induction of EAE. We measured
leukocyte infiltration and localization in the CNS using flow cytometric analysis and immunohistochemical
procedures. We determined levels of CD3 and selected chemokine and cytokine gene expression by quantitative
real-time PCR.
Results: IRF7 gene expression increased in the CNS as disease progressed. IRF7 message was localized to microglia
and infiltrating leukocytes. Furthermore, IRF7-deficient mice developed more severe disease. Flow cytometric
analysis showed that the extent of leukocyte infiltration into the CNS was higher in IRF7-deficient mice with
significantly higher number of infiltrating macrophages and T cells, and the distribution of infiltrates within the
spinal cord was altered. Analysis of cytokine and chemokine gene expression by quantitative real-time PCR showed
significantly greater increases in CCL2, CXCL10, IL-1b and IL17 gene expression in IRF7-deficient mice compared
with WT mice.
Conclusion: Together, our findings suggest that IRF7 signaling is critical for regulation of inflammatory responses
in the CNS.
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Background
Multiple sclerosis (MS) is a chronic inflammatory
demyelinating disease of the central nervous system
(CNS), which is likely triggered by infection or other
environmental events [1,2]. Experimental autoimmune
encephalomyelitis (EAE) is an animal model for MS that
is induced by immunization with myelin antigens [3]. In
both MS and EAE demyelinating lesions are accompa-
nied by T cell and macrophage infiltration [2,3].
The first clinically approved therapy for MS was IFN-
b [4,5], a member of the type I IFN family that also
includes multiple IFN-a subtypes. Type I IFNs are clas-
sically induced by viral infection and act through a com-
mon receptor, IFNAR [6]. The transcription factor IRF7
is constitutively expressed at low levels in the cytoplasm
[7,8], and becomes activated by innate receptor signal-
ing, resulting in translocation to the nucleus and induc-
tion of type I IFN [9]. Type I IFN signaling leads to
further induction of IRF7, so creating a feed-forward
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therefore represent a link between innate receptor and
type I IFN signaling. Consequently, changes in IRF7
function may affect processes regulated by type I IFN.
Mice lacking IRF7 are deficient in type I IFN responses
and consequently lack innate responsiveness to viruses
[10,11].
In addition to their antiviral function, type I IFNs play
a critical role in the regulation of inflammation in the
CNS [12]. Mice lacking either IFNb or IFNAR develop
more severe EAE, with increased CNS infiltration
[13-15]. Recent evidence suggests that type I IFN may
be produced within the CNS, in response to inflamma-
tion or injury, and that signaling through IFNAR modu-
lates leukocyte infiltration [7,8,16]. We have shown that
synaptic degeneration-induced IRF7 increase in the CNS
is IFNAR-dependent [8].
The signaling pathways mediating production and
effect of type I IFN in the CNS remain uncertain. Here
we analyze the role of IRF7 in EAE, and show that mice
lacking this transcription factor develop more severe
EAE, with increased CNS infiltration. This implicates
IRF7 as a key signaling intermediate in modulation of
autoimmune demyelinating disease. Due to its regula-
tory action on type I IFN signaling, IRF7 therefore
represents an important factor that regulates develop-
ment of CNS autoimmune diseases, such as MS.
Materials and methods
Animals
IRF7-KO mice on C57BL/6 (B6) background were pur-
chased from Riken BioResource Center (Tsukuba, Japan)
and maintained as a breeding colony. Control wild-type
B6 mice, which have been shown to be appropriate con-
trols for EAE studies [17], were obtained from Taconic
(RY, Denmark). Mice were provided with food and
water ad libitum. All experiments were approved by the
Danish Justice Ministry Committee on Animal Research
(Approval Number 2009/561-1724).
Induction of EAE and Clinical Evaluation
To induce EAE, adult female IRF7-KO and control B6
mice were subcutaneously immunized with 35-55 myelin
oligodendrocyte glycoprotein (35-33 MOG) peptide in
complete Freund’s adjuvant containing 2 mg/ml M.
tubercolosis in the flanks. In addition, mice received
intraperitoneal injections with 200 μl pertussis toxin (1,5
μg/ml) (Sigma-Aldrich, Brøndby, Denmark) at the time
of immunization and two days later. Mice were then
c a g e di ng r o u p so f8( 4W Tm i c ew i t h4I R F 7 - K O
mice). The mice were weighed and monitored daily for
clinical signs of EAE, which were scored as follows: 0,
no symptoms; 1, Weak or hooked tail; 2, Floppy tail; 3,
2 + hind limb paresis (weak hind limbs-assessed by the
animal’s slowness or splaying limbs when walking or
unsteady walk in the cage or on the lid of the cage),
Grade 4: 3 + very weak hind limbs or one hind limb
paralysed- hind limb paresis-assessed by the animal
dragging one or both hind limbs (not complete loss of
tonus in one or both hind limbs); 5, 4 + unilateral hind
limb paralysis (both hind limbs paralysed); 6, 5 + paresis
in one forelimb. Because of ethical reasons, mice were
euthanized when they reached a clinical score of 5. In
the first experiment the clinical score in first euthanized
4 mice was 3-4, and all other euthanized mice had clini-
cal score 5. At the end of experiment all remaining mice
were euthanized. In the second and third experiment,
half of the mice were sacrificed at day 15 and the rest
either when they scored 4-5 or at the end of experiment.
Mice were weighed and scored in a blinded manner.
Tissue preparation
Mice were deeply anaesthetized and perfused intracar-
dially with ice-cold Phosphate Buffered Saline (PBS).
Spinal cords were dissected out and processed as
followed:
For Histology: the tissues were placed in 4% parafor-
maldehyde (PFA) (Sigma-Aldrich) for 60 minutes and
overnight in 1% PFA at 4°C. The tissues were then
placed in 20% sucrose solution overnight, freeze-
embedded in cryo-embedding (Ax-lab, Vedbæk, Den-
mark), cut in 16-μm cryostat sections, mounted on glass
slides and stored at -80°C.
For Flow Cytometry: the tissues were placed in a plate
with Hanks Balanced Salt Solution (HBSS) (Invitrogen
A/S, Taastrup, Denmark) for further processing.
For Quantitative real-time reverse transcriptase- PCR
assay: the tissues were placed in eppendorf tubes con-
taining TRIzol (Invitrogen Life Technologies, Paisley,
Scotland, UK), which were then stored in -80°C until
further processing.
Histology
To investigate the extent and distribution of histopathol-
ogy Hematoxylin and Eosin staining was performed.
Double Immunostaining was used to detect astrocytes
and T-cells. In brief, sections were washed in PBS, fol-
lowed by rinsing in PBS-0.5% Triton (Triton- X-100)
(Sigma-Aldrich) (PBST) and blocked in a solution con-
taining PBST and 3% BSA (Sigma-Aldrich). Thereafter,
sections were incubated with Cy-3 conjugated mouse
anti GFAP antibody (C9205, Sigma-Aldrich), and Rat
anti-mouse CD3 (MCA500G, Serotec) antibodies, in
order to detect astrocytes and T cells respectively. After
several washes in PBST, sections were incubated with
donkey anti-rat Alexa Fluor-488 antibody (Invitrogen-
Molecular Probes, Taastrup, Denmark), to visualize anti-
CD3 antibody. Nuclei were then stained with DAPI
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staining, control sections were treated without primary
antibody or with isotype-matched primary antibodies.
Control sections displayed no staining comparable with
that seen without primary antibodies (not shown).
Images were acquired using an Olympus BX51 micro-
scope (Olympus, Denmark) connected to an Olympus
DP71 digital camera, and combined using Adobe Photo-
shop CS version 8.0 to visualize double-labeled cells.
Flow cytometry
Single cell suspensions of spinal cords and lymph nodes
(LN) were prepared by dissociation using a 70 μmc e l l
strainer (BD Biosciences, Brøndby, Denmark). Spinal
cord samples were resuspended in 37% Percoll (GE
Healthcare Bio-sciences AB, Uppsala, Sweden) and cen-
trifuged to remove myelin. Blocking was performed using
Mouse Fc Block (BD Biosciences). Cells were stained
with biotinylated anti-mouse CD8, FITC anti-mouse
CD4 or PerCP/Cy5.5 anti-mouse CD11b and phycoery-
thrin (PE) anti-mouse CD45 (BD Biosciences). Data was
collected on a FACS Calibur (BD Biosciences), and ana-
lyzed using Flowjo software (Tree Star, Ashland, OR).
T cell stimulation and intracellular cytokine staining
Single cell suspensions prepared as described above were
plated in 96 well plates coated with anti-mouse CD3ε
(145-2C11) and cultured for 9 hours to stimulate cytokine
production in T cells. GolgiPlug (BD Biosciences) was
added two hours after plating. After incubation, cells were
washed and stained with V500-rat anti mouse CD4 (BD),
PerCP/Cy5.5 anti-mouse CD8a (Biolegend) and either
allophycocyanin (APC)-anti-mouse CD196 (CCR6) (Biole-
gend) or biotin anti-mouse CD183 (CXCR3) (Biolegend)
and APC-Streptavidin (BD Biosciences). Intracellular cyto-
kine staining was performed using a Cytofix/Cytoperm kit
(BD). PE-rat anti-mouse IL17A (BD Biosciences), PE/Cy7
anti-mouse IFNg (Biolegend) were used to detect the cyto-
kines. Data was collected on an LSR II (BD Biosciences),
and analyzed using FACS DIVA software (BD).
Fluorescence Activated Cell Sorting
Samples were prepared as described above and stained
with V500-rat anti mouse CD4 (BD Biosciences),
PerCP/Cy5.5 CD11b (Biolegend), PerCP/Cy5.5 anti-
mouse CD8a (Biolegend), and either APC anti-mouse
CD196 (CCR6) (Biolegend) or Biotin anti-mouse CD183
(CXCR3) (Biolegend) and APC-Streptavidin (BD Bios-
ciences). Cells were sorted on a FACSVantage/Diva cell
sorter (BD Biosciences).
Quantitative Real-Time Reverse Transcriptase- PCR assay
Total RNA was purified using TRIzol RNA isolation
reagent (Invitrogen Life Technologies) according to the
manufacturer’s protocol for whole tissue RNA extraction.
One μg of RNA from each spinal cord sample was incu-
bated with Moloney murine leukemia virus RT (Invitrogen
Life Technologies) according to the manufacturer’s proto-
col, using random hexamer primers. Quantitative Real-
Time Reverse Transcriptase- PCR assay (Quantitative RT-
PCR) were performed using ABI Prism 7300 Sequence
Detection Systems (Applied Biosystems, Foster City, CA).
Quantitative RT-PCR was performed for IRF7, CCL2,
CXCl10, TNF-a,I L - 1 b,I F N g, IL17 and CD3, using primers
and probes as described previously [8,18]. 18s rRNA pri-
mers and probes (Applied Biosystems) were used as an
endogenous control to account for differences in the
extraction and RT of total RNA [8]. Each reaction was per-
formed in 25 μl with TaqMan 2× Universal PCR Master
Mix (Applied Biosystems), undiluted cDNA, primers, Taq-
Man probe, and 2× filtered sterile milliQ water. For all
genes, PCR conditions were 2 minute at 50°C, 10 minutes
at 95°C followed by 40 cycles each consisting of 15 seconds
at 95°C and 1 minute at 60°C. To determine the relative
RNA levels within the samples, standard curves for the
PCR were prepared using cDNA from a reference sample
and making fourfold serial dilutions. Relative expression
values were then calculated by dividing the expression level
o ft h et a r g e tg e n eb yt h ee x p r e s s i o nl e v e lo f1 8 sr R N A .
Statistical analysis
Data were analyzed by nonparametric, Mann-Whitney t-
test using GraphPad Prism software (GraphPad Software
Inc., San Diego, California, USA). A p value < 0.05 was
considered to be statistically significant. Data are pre-
sented as Mean ± SEM.
Results
Upregulation of IRF7 gene expression in EAE
IRF7 gene expression was measured in spinal cords from
WT mice that had been immunized with MOGp35-55
+CFA. The results from three experiments are combined in
Figure 1 and 1 show that induction of EAE leads to increased
IRF7 gene expression. In addition the up-regulation of IRF7
mRNA correlated with the clinical score (Figure 1A). Consis-
tent with the well-known widespread expression of Type I
IFN and its response elements, as well as with previous stu-
dies [7,8,16], we found expression of IRF7 mRNA by Th1
and Th17 CD4+ T cells, and by macrophages and microglia
(additional file 1 and Figure 1B). IRF7 gene expression
increased in CD45dimCD11b+ microglia during the course
of EAE nearly reaching the levels seen in CD45highCD11b+
myeloid cells infiltrating the CNS (Figure 1B).
IRF7-deficient mice develop more severe EAE compared
with WT
To assess the role of IRF7 in EAE, we immunized IRF7-
deficient mice with MOG in CFA with pertussis toxin, a
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independent experiments, the mean time of disease
o n s e tw a sn o ts i g n i f i c a n t l yd i f f e r e n tb e t w e e nW T
(12.99 ± 1.0 day) and IRF7-KO (12.07 ± 0.7 day)
(Table 1). However, the incidence of EAE differed,
being 29/39 (74%) versus 28/30 (93%) in WT and
IRF7-KO mice, respectively (Table 1). Nearly half of
the animals with EAE were euthanized at grade 5 in
the IRF7-KO group, compared to only 4/29 of those in
the WT group (Table 1). Whereas the number of mice
with EAE that did not achieve grade 3 was almost 50%
in WT groups, less than a quarter of IRF7-KO mice
failed to reach this level of severity (Table 1). Results
from one experiment are shown as mean clinical
scores in Figure 2A. IRF7 deficient mice developed sig-
nificantly more severe EAE symptoms (Figure 2A). The
need for ethical reasons to euthanize mice with severe
disease disallowed study of disease progression in
severely affected animals and may have obscured a sta-
tistically significant difference in severity. Increased
disease severity was paralleled by significantly greater
loss of whole body weight (Figure 2B).
Increased immune cell entry into IRF7-deficient CNS
We then investigated the effect of IRF7 gene deletion on
the infiltration of cells into the CNS. Flow cytometric
analysis showed the clinical score of both WT and
IRF7-deficient mice was correlated to the number of
infiltrating blood-derived cells, as expected. Blood-
derived CD45
highCD11b
+ macrophages were discrimi-
nated by their higher level ofe x p r e s s i o no fC D 4 5f r o m
CNS-resident microglia (Figure 3A). The total number
of infiltrating CD45
highCD11b
+ macrophages (p < 0.022,
Figure 3A, D), CD4+ (p < 0.022, Figure 3B, E) and CD8
+ T cells (p < 0.014, Figure 3C, F) was higher in IRF7-
KO compared with WT CNS with more severe EAE.
IRF7 deficiency affected distribution of infiltrating
immune cells in CNS
Fluorescence microscopy was used to localize infiltrating
cells in the CNS. CD3+ T cells were increased in num-
ber and more diffusely dispersed in white matter in the
spinal cord of IRF7-deficient mice with EAE, compared
to the more focal and constrained infiltration pattern in
WT spinal cord (Figure 4). In contrast to T cells, there
was no apparent effect of IRF7-deficiency on numbers
or distribution of GFAP+ astrocytes (Figure 4A, B). We
further examined CD3ε,I F N g and IL17 gene expression
by quantitative RT-PCR. The content of CD3ε and IFNg
mRNA was increased in spinal cords from both IRF7-
deficient and WT mice with EAE, but no significant dif-
ferences could be measured when CD3ε (p < 0.2086)
and IFN-g mRNA (p < 0.0649) were compared between
IRF-7 deficient and WT mice (Figure 4C, D). In con-
trast, IL-17 gene expression was higher (p < 0.0087) in
IRF7-KO spinal cord than in spinal cords from WT
mice with EAE (Figure 4E).
Figure 1 Upregulation of IRF7 mRNA in CNS.A )I n c r e a s e dI R F 7
gene expression correlated with clinical score. Values on Y axis are
levels of IRF7 mRNA normalized to 18S rRNA expression. Values on
the × axis show clinical score. B) Increased IRF7 gene expression by
CD45dimCD11b+ microglia at peak disease was not statistically
significant different from levels in CNS-infiltrating CD45highCD11b+
myeloid cells. ND: not detected; UNM: unmanipulated WT B6 mice.
Table 1 Relative incidence, onset, and severity of EAE in IRF7-deficient and control mice
Incidence Onset (day) # mice with EAE that did not reach Grade 3 # mice reaching Grade 5
a # mice showing remission
b
Wild-type 29/39 12.99 ± 1.0 11/29 4/29 7/29
IRF7-KO 28/30 12.07 ± 0.7 6/28 12/28 2/28
a: Progression to Grade 5 was in all cases rapid and resulted in euthanasia before day 18.
b: Reduction in severity of EAE by one grade was defined as remission.
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deficient mice
To further investigate the role of IRF7 on Th1 and Th17
cells during EAE, we measured IFNg and IL17 produc-
tion by CD4+ T cells from spinal cords and LN. IRF7
deficiency did not affect percentages of T cells produ-
cing these cytokines in spinal cord (not shown). How-
ever, lack of IRF7 resulted in an increase (p < 0.006) in
the percentage of CD4+IFNg+ cells (Figure 5), but not
in CD4+IL17+ T cells (not shown) in LN.
Elevated CCL2, CXCL10 and IL-1b expression in IRF7-
deficient EAE
We next examined whether lack of IRF7 affected the
expression of inflammatory mediators that are known to
Figure 2 IRF7-KO mice develop more severe EAE.A )C l i n i c a l
score of mice with EAE. IRF7 deficient mice (n = 8) developed more
severe EAE than WT B6 control (n = 16) as indicated by the asterisk.
B) Change in whole body weights as percent of weight one day
prior to immunization (Day 0). * P < 0.05, ** p < 0.01.
Figure 3 IRF7 deficient mice had more CNS-infiltrating cells.A -
C) Example of FACS profiles of CNS from IRF7-KO mice with EAE.
FACS profiles show CD45
highCD11b
+ macrophages (A), CD4+ T cells
(B), and CD8+ T cells (C). IRF7-KO mice (n = 7) had more infiltrating
CD45
highCD11b
+ macrophages (D), CD4+ (E) and CD8+ (F) cells in
the CNS compared to WT mice (n = 6).
Figure 4 CD3, GFAP, DAPI Immunostaining and quantitative
real-time PCR analysis of T cells and related cytokines in IRF7-
KO and WT mice with EAE. CD3+ T cells were dispersed more
diffusely in the spinal cord of IRF7-deficient mice with EAE (B)
compared to the more focal infiltration pattern in WT spinal cord
(A). IRF7 deficiency had no apparent effect on GFAP+ cells
(astrocytes). A-B) original magnification 20×. C-E). CD3ε (C), IFN-g (D),
and IL-17 (E) gene expression in the CNS of IRF7-deficient (n = 6-7)
and WT mice (n = 5-7) were calculated and normalized to 18s rRNA.
Figure 5 IRF7 deficiency resulted in increased percentage of
CD4+IFNg+ T cells in LN. After immunization with MOGp35-55 in
CFA, IRF7-KO mice showed a significantly greater percentage of
CD4+IFNg cells in LN compared to similarly-immunized WT mice.
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of the chemokines CCL2, CXCL10, and cytokines IL-1b
and TNF-a increased in EAE and correlated to clinical
severity (not shown). Quantitative RT-PCR analysis
showed that the increases in expression of CCL2 (p <
0.0176, Figure 6A) and CXCL10 (p < 0.0111, Figure 6B),
IL-1b (p < 0.0260, Figure 6C) and TNF-a (p < 0.0530,
Figure 6D) were higher in IRF7-deficient spinal cord
than in spinal cord from WT mice with EAE.
Discussion
T h ep a t h o g e n e s i so fM Sa n di t sa n i m a lm o d e l si n c l u d e
immune cell activation and their infiltration to the CNS,
causing demyelination and axonal damage. The activa-
tion of immune cells involves innate receptor signaling
[19], that is up-regulated in mice with EAE and modu-
lates pathogenesis of EAE [20,21]. The innate receptor
signaling that induces type I IFN, involves IRF7 [22].
IRF7 is activated by innate receptor signaling and regu-
lates the induction of type I IFN. Type I IFN signaling
further induces IRF7. It has been shown that the level of
IFN-b in the CNS was increased in mice with EAE [13].
In concordance with this, we show that levels of IRF7
are increased with EAE severity. Thus, the increased
IRF7 expression may represent a protective function for
IRF7 in EAE.
T h em e c h a n i s mb yw h i c ht y p eII F N sr e g u l a t eC N S
inflammation has been shown to include reduction of
leukocyte migration to the CNS and inhibition of T cell
responses [23,24]. Our findings support the former role.
IFN-b has been widely used in treatment of MS, and
effects of type I IFN in animal models are generally
similar to clinical findings. Oral administration of IFN-a
to rats caused reduction of inflammation and
ameliorated EAE symptoms [23]. Similarly, treatment
with IFN-b could ameliorate EAE in rats and was asso-
ciated with a reduction in the number of infiltrating leu-
kocytes to the CNS [25,26]. In addition, IFN-b deficient
mice develop more severe EAE with increased leukocyte
infiltration [14]. This was supported by studies in
IFNAR deficient mice that likewise showed more severe
EAE with increased infiltration [13,20]. Here we show
that IRF7 deficiency resulted in more severe EAE with
higher leukocyte infiltration than WT mice with EAE.
Our findings point to IRF7 as a key signaling intermedi-
ate in modulation of autoimmune demyelinating disease,
and open the possibility that innate signals may also be
protective.
Leukocyte infiltration is regulated by chemokines and
cytokines and previous studies have shown that CCL2
and CXCL10 play a key role in attracting leukocytes to
the CNS in both EAE and after brain injury [13,27,28].
I nt h ep r e s e n ts t u d yw es h o wt h a tt h ei n c r e a s ei n
CCL2 and CXCL10 during EAE was significantly
higher in IRF7 deficient mice compared with WT
mice. The increased chemokine expression in the CNS
might either be secondary to increased entry of periph-
eral immune cells, which are a potential source of sev-
eral chemokines and cytokines, or could be due to
direct effect of IRF7 on chemokine expression, or to a
combination of the two. It has been demonstrated that
innate receptor and type I IFN signaling regulate che-
mokine expression [22,29-31], but whether lack of
IRF7 directly leads to increased chemokine and cyto-
kine expression is not known. It has been shown that
endogenous IFN-b selectively inhibits TNF-a,b u tn o t
IL-1b expression [14], whereas in another study it was
shown that IFN-b enhanced production of both [32]. It
is also shown that deficiency in IFNAR resulted in
reduced CXCL10 expression, but had no effect on
CCL2 [8,31]. The effect of type I IFN signaling on pro-
duction of chemokine and cytokines seems to depend
on context.
However, in line with our observation in this study,
Prinz et al., showed that CXCL10 and CCL2 levels in
IFNAR-deficient mice increased [13]. CCL2 and
CXCL10 chemokines are known to control both degree
and pattern of leukocyte entry [33-35], and correspond-
ingly we show that the increased chemokine level was
associated with increased and more disseminated
infiltration.
Taken together this could suggest that IRF7 regulates
leukocyte infiltration through type I IFN regulated che-
mokine release. Alternatively, regulation could be
mediated through IFN-independent mechanisms, by
which IRF7 independently inhibits leukocyte migration,
for instance by blocking the release of chemokines. IRF7
could also influence leukocyte entry to the CNS through
Figure 6 Changes in cytokine and chemokine gene expression
in IRF7 deficient (n = 6-7) and WT mice (n = 6-7). Real-time PCR
analysis of CCL2 (A), CXCL10 (B), IL-1b (C) and TNF-a (D) showing
these gene expression levels.
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proteinase or adhesion molecules [36-38].
MS is considered to be a T cell mediated autoimmune
disease. It has been shown that IFN-g secreting Th1 and
IL-17 secreting Th17 cells play a crucial role in EAE
[39,40], although neither cytokine is absolutely required
for EAE [41,42]. The ratio of Th17 and Th1 has been
reported to be crucial for the localization of infiltration
in CNS of mice with EAE [43]. It has been shown that
innate receptor induced type I IFN is essential in limit-
ing Th17 development and autoimmune inflammation
[20,44]. In concordance, we find that IRF7 deficient
mice had significantly higher number of T cells in the
CNS compared with WT mice with EAE. Additionally,
both IL17 and IFNg were expressed at higher levels in
the CNS of IRF7 deficient mice compared with WT.
Our findings point to IRF7 as a key signaling intermedi-
ate in type I IFN modulation of autoimmune disease.
We used CXCR3 and CCR6 as surrogate markers for
Th1 and Th17 respectively to show that IRF7 is
expressed by both Th1 and Th17 CD4+ T cells and that
IRF7 levels do not change significantly as mice progress
through EAE. This suggests that both Th1 and Th17
could be affected by IRF7-deficiency. Consistent with
this, both IFNg and IL17 were increased in CNS. Galli-
g a ne ta l . ,a n dG u oe ta l . ,s h o w e dt h a tI F N b or IFNAR
signaling inhibited Th17 development, and Guo et al.,
also showed that TRIF signaling inhibited both Th1 and
Th17, consistent with our findings [15,20]. It also can-
not be excluded that enhanced Th1 and Th17 responses
in our study reflected altered activity of antigen-present-
ing cells, since macrophages, dendritic cells and micro-
glia can all express CD11b and so were potentially
affected by IRF7-KO. Dissection of the relevant cell type
(s) whose IRF7 response controlled inflammatory T cell
induction would require lineage-specific knockouts, such
as were used by Prinz and colleagues [13]. We then per-
formed intracellular cytokine staining of CD4+ T cells
from LN and spinal cords. The percentages of CD4
+IFNg+ and CD4+IL17+ T cells in the spinal cords were
unaffected by IRF7 deficiency. However, the percentages
of CD4+IFNg+ cells in the lymph nodes increased in
IRF-KO mice. Our data had already shown increased
expression of both IFNg and IL17 in CNS of IRF7 KO
mice, though only to significance for IL17. Modulation
of Th1 development and IFNg production by Type I
IFN has been described by others [14,45,46]. The differ-
ences in data obtained from intracellular cytokine stain-
ing and cytokine message measured in spinal cords
could be attributed to the fact that IL17 message
detected by PCR in IRF7-KO could originate from
sources other than T cells in the CNS.
EAE also involves gamma-delta T cells which do not
express either CD4 or CD8 [47], and we can speculate
t h a tt h el a c ko fc o r r e s p o n d e n c et h a tw eh a v es h o w n
b e t w e e nC D 3m R N Aa n dC D 4a n dC D 8n u m b e r sm a y
indicate differential effect of Type I IFN signaling on
this subset. Alternatively it is possible that CD3 mRNA
levels were downregulated in activated IRF7-KO T cells.
Genetic factors contribute to an individual’sr i s ko f
developing autoimmune disease. The transcription fac-
tors IRF5 and IRF8 that are involved in both innate
receptor and type I IFN signaling pathways have been
identified as risk genes associated with MS [48,49]. IRF7
itself has been identified as a risk factor for human sys-
temic lupus erythematosus [50] and has been shown to
be co-regulated along with IRF8 in MS [49]. In the pre-
sent study, we demonstrate functional significance of
IRF7 in regulation of EAE. This would argue for loss of
function as the probable basis for IRF7 as a risk factor
in MS, although such association or its mechanism has
not been established.
Conclusion
Administration of IFN-b as therapy is beneficial for MS
and it needs to be considered whether and how endo-
genous IFN I signaling would also contribute to disease
modulation. Our results point to IRF7 as controlling the
immunoregulatory effects of IFN-b and potentially act-
ing to direct both innate and IFNAR signals towards
regulatory pathways. This opens possibilities for a pre-
cise targeting of signaling pathways in MS. Future stu-
dies on treatment of MS may therefore consider IRF7 as
therapeutic target.
Additional material
Additional file 1: Expression of IRF7 by cell subsets in LN. IRF7 gene
expression was measured by qRT-PCR in CXCR3+CD4+, CCR6+CD4+ and
CD45+CD4-CD8- cells, sorted from LN of immunized mice. Days after
immunization are shown on the × axis. No statistically significant
differences in IRF7 gene expression were detected between these
populations. Columns show means, error bars show SEM. ND: not
detected.
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